Regulatory Risks of Compounded GLP-1s

The real risk is that vertical integration turns a regulatory change into a full stack problem. When a telehealth company also controls compounding, manufacturing, and fulfillment, scrutiny of compounded GLP-1s can hit the drug itself, the marketing, and the operating workflow at once. That matters because compounded GLP-1s had become a high margin way for platforms like Hims & Hers to offer cheaper obesity treatment when branded coverage was limited.

• During the 2023 to 2024 shortage, D2C platforms used compounded semaglutide and tirzepatide to offer $199 to $499 monthly options, and the economics were unusually strong, with gross margins around 80% because the platform owned intake, prescribing, fulfillment, and follow up in one flow.
  2 sacra
• That window narrowed in 2025. FDA ended or phased out enforcement discretion tied to shortage status for compounded semaglutide and tirzepatide, then expanded enforcement against mass marketed non approved GLP-1s and misleading telehealth promotion. This makes internal compounding assets less of a moat and more of a compliance surface area.
  3 fda 4 fda 5 fda
• Peers have already shifted toward branded manufacturer channels instead. Ro and Hims & Hers moved more volume through LillyDirect and NovoCare style cash pay pathways, which preserve the telehealth front end but move drug supply back to approved manufacturer rails.
  2 sacra 6 hims

Going forward, the winners in obesity care will look less like compounders and more like demand routers with strong care management. Telehealth platforms can still own patient acquisition, eligibility checks, dose changes, labs, and coaching, but the drug itself is likely to move onto tighter manufacturer and FDA governed channels, which favors infrastructure models with less direct product liability.